Catalyst

Slingshot members are tracking this event:

Bristol-Myers Squibb (BMY) Releases Phase 3 ONO-4538-12 Results Evaluating Opdivo in Patients with Unresectable Advanced or Recurrent Gastric Cancer Resistant to Standard Therapy

Source Link:
http://investor.bms.com/investors/news-and-events/press-releases/press-release-details/2016/Opdivo-nivolumab-Demonstrates-Overall-Survival-Benefit-in-Patients-With-Unresectable-Advanced-or-Recurrent-Gastric-Cancer-in-Phase-3-Study/default.aspx

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BMY
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Nov 10, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Ono-4538-12, Opdivo, Unresectable Advanced, Recurrent, Gastric Cancer, Resistant To Standard Therapy
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.